ALLN 177

Drug Profile

ALLN 177

Alternative Names: ALLN-177

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Allena Pharmaceuticals
  • Class Enzymes
  • Mechanism of Action Oxalate inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperoxaluria
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperoxaluria

Most Recent Events

  • 11 Mar 2017 Phase II development is ongoing for secondary hyperoxaluria in USA (PO)
  • 01 Jan 2017 Allena Pharmaceuticals completes a phase IIb study for Hyperoxaluria in USA (NCT02503345)
  • 01 Jan 2017 Allena Pharmaceuticals completes a phase II trial for Hyperoxaluria in USA (NCT02547805)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top